G. Pappagallo
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Cancer, Lipids, and Metabolism, Bladder and Urothelial Cancer Treatments, Cancer Treatment and Pharmacology, Prostate Cancer Diagnosis and Treatment
Most-Cited Works
- → Vinorelbine (VNR) plus best supportive care (BSC) vs. BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial(1998)18 cited
- → 966 Is there a difference in quality of life between BCG and intravesical chemotherapy? Results of a randomized phase II study(2012)3 cited
- → A multicentric phase II randomized trial of docetaxel (D) plus estramustine (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC)(2006)3 cited
- → 464 A randomized, open-label, multicentre study of efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate (HA 1.6% and CS 2%) vs dimethyl sulfoxide (DMSO 50%) in women with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC)(2014)3 cited
- → Docetaxel (D) and estramustine (E) as first-line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC): Final results of a multicentric phase II randomized trial(2007)2 cited
- → The Effect of Acute Bladder Filling on Plasmatic Antidiuretic Hormone Production in Healthy Adult Volunteers(2002)1 cited
- → 596 Survival in muscle-invasive bladder cancer: Comparison between primary and progressive disease(2004)
- → Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)(2019)
- → 305 RESULTS OF A MULTICENTRIC PHASE II RANDOMIZED TRIAL WITH DOCETAXEL (D) ± ESTRAMUSTINE (E) AS FIRST LINE CHEMOTHERAPY FOR PATIENTS (PTS) WITH HORMONE-REFRACTORY ADVANCED PROSTATE CANCER (HRPC)(2007)
- → 7050 POSTER Multiple Docetaxel (DOC) Re-challenges (ReC) in Castration-resistant Prostate Cancer (CRPC) Patients (pts) – Outcomes and Predictive Factors of Response(2011)